Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA617 in combination with ipilimumab and nivolumab for men with metastatic castrationresistant prostate cancer (mCRPC; ANZUP 2001).Shahneen Sandhu,Shalini Subramaniam,Michael S. Hofman,Martin R. Stockler,Andrew James Martin,Izabella Pokorski, Jeffrey C. Goh,David A. Pattison,Nattakorn Dhiantravan,Craig Gedye,Natalie K. Rutherford,Anthony M. Joshua,Thean Hsiang Tan,Ian D. Kirkwood,Andrew James Weickhardt, Sze Ting Lee,Ramin Alipour,Andrew Nguyen,Ian D. Davis,Louise EmmettJOURNAL OF CLINICAL ONCOLOGY（2023）引用 0|浏览4暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
